A5023354062- Glioma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Radiomics and Machine Learning in Medical Imaging
- Cancer Genomics and Diagnostics
- Cancer Research and Treatments
- Brain Metastases and Treatment
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Nanoplatforms for cancer theranostics
- CNS Lymphoma Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Medical Imaging Techniques and Applications
- Immune cells in cancer
- Cancer Treatment and Pharmacology
- Ferroptosis and cancer prognosis
- MRI in cancer diagnosis
- Peptidase Inhibition and Analysis
- Vascular Tumors and Angiosarcomas
- Epigenetics and DNA Methylation
- RNA Interference and Gene Delivery
- Advanced MRI Techniques and Applications
- Cytokine Signaling Pathways and Interactions
- Protease and Inhibitor Mechanisms
- Cancer, Hypoxia, and Metabolism
Albert Einstein College of Medicine
2023-2024
Montefiore Medical Center
2023-2024
Montefiore Einstein Comprehensive Cancer Center
2024
Icahn School of Medicine at Mount Sinai
2014-2023
Tisch Cancer Institute
2014-2022
Tisch Hospital
2015-2022
Memorial Sloan Kettering Cancer Center
1996-2016
Mount Sinai Hospital
2016
Mount Sinai Medical Center
2015
Cornell University
2003-2013
Colon cancer stem cells are believed to originate from a rare population of putative CD133+ intestinal cells. Recent publications suggest that small subset colon expresses CD133, and only these capable tumor initiation. However, the precise contribution tumor-initiating in mediating metastasis remains unknown. Therefore, temporally spatially track expression CD133 adult mice during tumorigenesis, we generated knockin lacZ reporter mouse (CD133lacZ/+), which is driven by endogenous promoters....
Purpose We previously reported a series of patients treated with high-dose methotrexate (MTX) -based chemotherapy, or without whole brain radiotherapy. The purpose this report is to update the initial results and provide long-term data regarding overall survival, patterns relapse, risk treatment-related neurotoxicity. Patients Methods Fifty-seven an average age 65 median Karnofsky performance score 70 were treated; all have been observed longitudinally serial magnetic resonance imaging scans...
Abstract Purpose: Biomarkers can facilitate diagnosis, monitor treatment response, and assess prognosis in some patients with cancer. YKL-40 matrix metalloproteinase-9 (MMP-9) are two proteins highly differentially expressed by malignant gliomas. We obtained prospective longitudinal serum samples from gliomas to determine whether or MMP-9 could be used as markers. Experimental Design: Serum were concurrently magnetic resonance imaging scans. determined ELISA the values correlated patient's...
Alternative dosing schedules of temozolomide may improve survival in patients with newly diagnosed glioblastoma (GBM) by increasing the therapeutic index, overcoming common mechanisms resistance, or both. The goal this randomized phase II study was to evaluate two different regimens adjuvant treatment GBM.Adult GBM were randomly assigned receive standard radiotherapy concurrent daily followed six cycles either dose-dense (150 mg/m(2) days 1 7 and 15 21) metronomic (50 continuous daily)...
High-grade gliomas are associated with a dismal prognosis. Notch inhibition via the gamma-secretase inhibitor RO4929097 has emerged as potential therapeutic option based on modulation of cancer-initiating cell (CIS) population and presumed antiangiogenic role.In this phase 0/I trial, 21 patients newly diagnosed glioblastoma or anaplastic astrocytoma received combined temozolomide radiotherapy. In addition to establishing MTD, study design enabled exploratory studies evaluating tumor brain...
Abstract Purpose: Bevacizumab is associated with decreased vascular permeability that allows for more aggressive radiotherapy schedules. We conducted a phase II trial in newly diagnosed glioblastoma utilizing novel hypofractionated stereotactic (HFSRT) schedule combined temozolomide and bevacizumab. Experimental Design: Patients tumor volume ≤60 cc were treated HFSRT (6 × 6 Gy to contrast enhancement 4 FLAIR hyperintensity dose painting) concomitant/adjuvant bevacizumab at standard doses....
Primary ocular lymphoma (POL), a of the globe, is restricted form primary central nervous system (PCNSL) that often progresses to brain and meninges; frequently it misdiagnosed until (CNS) develops. The optimal treatment has not yet been identified. We retrospectively reviewed course POL in 31 patients. Seventeen patients were treated for isolated (group A) 14 only after CNS disease was diagnosed B). both groups consisted systemic chemotherapy, chemotherapy plus radiotherapy (RT) or RT...
BackgroundIn this phase II trial, we investigated the efficacy of a metronomic temozolomide schedule in treatment recurrent malignant gliomas (MGs).
Differentiation of radiation necrosis (RN) from recurrent tumor (RT) in treated patients with glioblastoma remains a diagnostic challenge. The purpose this study is to evaluate the performance multiparametric MRI distinguishing RN RT glioblastoma, use combination MR perfusion and diffusion parameters.Patients who had new enhancing mass develop after completing standard treatment were retrospectively evaluated. Apparent coefficient (ADC), volume transfer constant (Ktrans), relative cerebral...
The treatment of glioblastoma (GBM) poses challenges. use immune checkpoint inhibition (ICI) has been disappointing as GBM is characterized by low mutational burden and T-cell infiltration. combination ICI with other modalities may improve efficacy.
(1) Background: Gliomas are the most common primary brain neoplasms accounting for roughly 40−50% of all malignant central nervous system tumors. We aim to develop a deep learning-based framework automated segmentation and prediction biomarkers prognosis in patients with gliomas. (2) Methods: In this retrospective two center study, were included if they had diagnosis glioma known surgical histopathology preoperative MRI FLAIR sequence. The entire tumor volume including hyperintense...
In patients with gliomas, isocitrate dehydrogenase 1 (IDH1) mutation status has been studied as a prognostic indicator. Recent advances in machine learning (ML) have demonstrated promise utilizing radiomic features to study disease processes the brain. We investigate whether ML analysis of multiparametric from preoperative Magnetic Resonance Imaging (MRI) can predict IDH1 glioma. This retrospective included glioma known and MRI. Radiomic were extracted Fluid-Attenuated Inversion Recovery...
Abstract Background Physiologic changes quantified by diffusion and perfusion MRI have shown utility in predicting treatment response glioblastoma (GBM) patients treated with cytotoxic therapies. We aimed to investigate whether quantitative after immune checkpoint inhibitors (ICIs) would determine 6-month progression-free survival (PFS6) recurrent GBM. Methods Inclusion criteria for this retrospective study were: (i) diagnosis of GBM ICIs (ii) availability pre post ICI (iii) at ≥6 months...
Early identification of glioma molecular phenotypes can lead to understanding patient prognosis and treatment guidance. We aimed develop a multiparametric MRI texture analysis model using combination conventional diffusion predict wide range biomarkers in patients with glioma.In this retrospective study, were included if they (1) had diagnosis gliomas known IDH1, EGFR, MGMT, ATRX, TP53, PTEN status from surgical pathology (2) preoperative including FLAIR, T1c+ for radiomic analysis....
2004 Background: Novel T cell-enabling therapies plus checkpoint inhibition may improve OS in GBM. INO-5401 (synthetic DNA plasmid encoding hTERT, WT-1, PSMA) INO-9012 IL-12), with cemiplimab (PD-1 inhibitor), was given to patients newly diagnosed GBM MRD evaluate tolerability, efficacy, and immunogenicity. Median immunogenicity at 18 months (OS18) are reported. Methods: This is a phase I/II, single arm, two cohort (A: unmethylated MGMT B: methylated MGMT) study. Primary endpoint safety;...
Purpose: The T2-FLAIR mismatch sign has shown promise in determining IDH mutant 1p/19q non-co-deleted gliomas with a high specificity and modest sensitivity. To develop multi-parametric radiomic model using MRI to predict co-deletion status patients newly diagnosed IDH1 glioma perform comparative analysis sign+. Methods: In this retrospective study, diagnosis of known who had preoperative were included. was evaluated independently by two board-certified neuroradiologists. Texture features...
To evaluate YKL-40 and MMP-9 proteins as tumor biomarkers in serum samples from patients with primary central nervous system lymphoma (PCNSL).In this prospective longitudinal study, consecutive histologically confirmed PCNSL were collected concurrently magnetic resonance imaging (MRI) scans at multiple time points analyzed for levels of by enzyme-linked immunosorbent assay. Marker correlated to disease status survival.Forty-five accrued. Median follow-up survivors was 25 months, 21 (47%)...